Syphilis Treatment Follow-Up (RPR with Titer)
Label Mnemonic: STFP
Epic code: LAB8648
Downtime form: A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery
Chemistry
6240 RCP
356-3527
Specimen(s):
Serum
Collection Medium:
BD Gold SST 5 mL Vacutainer
Minimum:
5 mL serum from a BD Gold SST tube
Rejection Criteria:
CSF and other body fluids.
Turn Around Time:
1 day
Reference Range:
Non-reactive (< 1:1)
Comments:
If RPR is weakly reactive or reactive, then a titer to endpoint will be added.

This test is intended for assessing treatment efficacy in patients who have been treated for syphilis. Successful treatment is generally indicated by a 4-fold reduction in RPR titer (e.g., 1:32 to 1:8).

Assay methodology changed to BioRad Bioplex method April 3, 2018.

For routine syphilis testing, "Syphilis Total Antibodies" should be ordered.
Test Limitations:
The assay is unaffected by icterus < 66 mg/dL, hemolysis (Hb < 500 mg/dL), or lipemia < 2000 mg/dL). RPR assay interference resulting in false positive results may occur with cross-reacting antibodies from patients diagnosed with systemic lupus erythematosus, malaria, autoimmune disease, viral pneumonia, and people who have been recently vaccinated (including vaccines for SARS-CoV-2). RPR results should be interpreted in conjunction with patient history, risk factors, and other syphilis testing.
Methodology:
Fluorescent Immunoassay
CPT Code:
86592 RPR; if reflexed, add 86593 RPR titer